Tongji-Ezhou Prospectively Cohort Study
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Enrollment
- 10,000
- Locations
- 1
- Primary Endpoint
- Diabetic complications
Study Overview
Brief Summary
Tongji-Ezhou study (TJEZ) is a prospective cohort study launched at 2013 in EZhou city, Hubei province, with the goal of recruiting and assessing 10,000 individuals and then following them for at least 2 decades. In addition, blood samples would be collected every 3-5 years among 6000 of them to investigate the nutritional biomarkers and potential determinants of chronic diseases such as obesity, type 2 diabetes, metabolic syndrome, and cardiovascular disease.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 20 Years to 80 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •(i) permanent residence in Ezhou district (minimum of 9 months); (ii) written informed consent; (iii) age ≥ 20 years old at the time of enrolling in the study.
Exclusion Criteria
- •(i) with chemotherapy or radiotherapy for cancer and other severe diseases.
Outcomes
Primary Outcomes
Diabetic complications
Time Frame: mean follow up of 10 years
Development of diabetic complications
Incidence of diabetes
Time Frame: 5 years
Type 2 diabetes was diagnosed when FPG ≥ 7.0 mmol/L and/or OGTT2h ≥ 11.1 mmol/L, or using diabetic medication (self-report).
Incidence of metabolic syndrome
Time Frame: 5 years
Metabolic syndrome is defined as using the updated National Cholesterol Education Program/Adult Treatment Panel III criteria for Asian Americans. These criteria require three or more of the following components: (1) central obesity (waist circumference of ≥90 cm for men or ≥80 cm for women), (2) triglycerides of ≥1.7 mmol/L, (3) HDL-C of \<1.03 mmol/L for men or \<1.30 mmol/L for women, (4) blood pressure of ≥130/85 mmHg or on medication for hypertension, and (5) fasting glucose of ≥5.6 mmol/L.
Incidence of cardiovascular diseases
Time Frame: mean follow up of 10 years
Cardiovascular death, stroke, myocardial infarction, heart failure
Secondary Outcomes
No secondary outcomes reported
Investigators
Liegang Liu
Vice dean of School of Public Health, Tongji Medical College
Huazhong University of Science and Technology